Taking part in GameChanger is simple.
Join thousands of others and help us drive dementia research forward simply using your smartphone.
- Sign up to the GameChanger research project
- Download the app to your smartphone
- Begin playing fun, free brain games!
Help us advance dementia research
Anyone over the age of 18, who doesn't have dementia, can take part.
Visit the GameChanger website to register.
Actor Kevin Whately, whose mother had Alzheimer’s disease, is supporting GameChanger
What is GameChanger?
GameChanger is a research project led by University of Oxford and supported by Alzheimer’s Society.
Over12,000 people are now supporting dementia research simply using their smartphones.
Why should you be a GameChanger?
It will help us understand more about how the brain works to support research that could prevent, slow down, or even stop the progression of dementia in future.
Researchers can paint a picture of how the brain works from the way we interact with our smartphones. If researchers know more about how the brain works, they hope to be able to spot the very early changes in the brains of people with dementia in the future, and use this information to develop new treatments.
Unite with thousands of others across the UK and be a GameChanger. Simply download our app and playing fun, free ‘brain games’ for five minutes each day for a month.
Will there be a GameChanger round three?
One of the most important things about GameChanger is that it will help us to understand how our memory and thinking skills change with time. GameChanger will be inviting everyone who took part in round 1 and 2 to complete a third month of brain games the following year.
However for participants that signed up to GameChanger in late 2018 and early 2019, round 3 has been delayed until 2022 owing to COVID-19 related reasons. The team will be in touch in 2022 to invite you to take part again.
So, please keep an eye out for their email!
Have a query? Check out our Frequently Asked Questions.
All data will be stored on secure server at the University of Oxford and only shared with the research community once anonymised.
The development of the app was funded by Roche pharmaceutical, Eli-Lilly pharmaceuticals, the Robertson Foundation and Oxford Health NHS FT Biomedical Research Centre.